HK1052870A1 - 诱导癌细胞死亡和肿瘤消退的方法 - Google Patents

诱导癌细胞死亡和肿瘤消退的方法 Download PDF

Info

Publication number
HK1052870A1
HK1052870A1 HK03105046.0A HK03105046A HK1052870A1 HK 1052870 A1 HK1052870 A1 HK 1052870A1 HK 03105046 A HK03105046 A HK 03105046A HK 1052870 A1 HK1052870 A1 HK 1052870A1
Authority
HK
Hong Kong
Prior art keywords
methods
cell death
cancer cell
tumor regression
inducing cancer
Prior art date
Application number
HK03105046.0A
Other languages
English (en)
Chinese (zh)
Inventor
Q. Daley George
Original Assignee
Q. Daley George
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q. Daley George filed Critical Q. Daley George
Publication of HK1052870A1 publication Critical patent/HK1052870A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03105046.0A 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法 HK1052870A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
US60/238,240 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
HK1052870A1 true HK1052870A1 (zh) 2003-10-03

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105046.0A HK1052870A1 (zh) 2000-10-05 2001-10-05 诱导癌细胞死亡和肿瘤消退的方法

Country Status (14)

Country Link
US (1) US6777415B2 (https=)
EP (1) EP1322334A2 (https=)
JP (1) JP2004510733A (https=)
CN (1) CN1479630A (https=)
AU (2) AU2002211862B2 (https=)
BR (1) BR0114430A (https=)
CA (1) CA2424797C (https=)
HK (1) HK1052870A1 (https=)
HU (1) HUP0302913A3 (https=)
MX (1) MXPA03003011A (https=)
NO (1) NO20031531L (https=)
NZ (1) NZ524936A (https=)
WO (1) WO2002028381A2 (https=)
ZA (1) ZA200302523B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
EP1654377A4 (en) * 2002-03-01 2010-03-24 Roger Williams Hospital PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
JP2009516167A (ja) * 2005-11-11 2009-04-16 ロジャー・ウィリアムズ・ホスピタル 癌処置における予測マーカーとしてのｐ６６−ｓｈｃ
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011034A1 (en) 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
CA2293433C (en) * 1997-06-17 2009-09-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
ZA985205B (en) * 1997-06-17 1998-12-15 Schering Corp Novel n-substituted urea inhibitors of arnesyl-protein transferase
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6383790B1 (en) 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
AU2002211862B2 (en) 2007-03-15
NO20031531D0 (no) 2003-04-04
HUP0302913A2 (hu) 2003-12-29
CN1479630A (zh) 2004-03-03
JP2004510733A (ja) 2004-04-08
MXPA03003011A (es) 2003-07-14
HUP0302913A3 (en) 2005-05-30
NO20031531L (no) 2003-06-05
WO2002028381A3 (en) 2003-03-27
AU1186202A (en) 2002-04-15
EP1322334A2 (en) 2003-07-02
US6777415B2 (en) 2004-08-17
NZ524936A (en) 2005-08-26
BR0114430A (pt) 2004-01-06
US20020128280A1 (en) 2002-09-12
CA2424797C (en) 2009-12-29
WO2002028381A2 (en) 2002-04-11
CA2424797A1 (en) 2002-04-11
ZA200302523B (en) 2004-08-24

Similar Documents

Publication Publication Date Title
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
WO2002028381A3 (en) Methods of inducing cancer cell death and tumor regression
MY117961A (en) Inhibitors of farnesyl protein transferase
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
EE04582B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064226A3 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
PL338555A1 (en) Method of preventing or treating oestrogen-dependent diseases and disorders
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
MY137303A (en) Methods for treating proliferative diseases
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
WO2001091767A3 (en) Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins
AU1397901A (en) Therapy with cannabinoids in the treatment of cerebral tumor
WO2002017952A3 (en) Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma